Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

NCT05870475 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Polycythemia Vera

Interventions

DRUG: Ruxolitinib
DRUG: Pegylated interferon α-2b

Sponsor

Institute of Hematology & Blood Diseases Hospital, China